Lenvatinib: beside a new treatment under test
104 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 2. Open to participants first (60), then studies with results posted, then the rest; newest registration first within each.
- Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid TumorsNot yet recruitingNCT07933419Phase 1/2Report a problem
- Pucotenlimab, Lenvatinib, and SBRT Before Surgery for Localized Clear Cell Renal Cell CarcinomaNot yet recruitingNCT07922915Phase 2Report a problem
- MRG003 Added to Ongoing Treatment After Progression in EGFR-Positive Advanced Thyroid CancerRecruitingNCT07874321Phase 2Report a problem
- Cryoablation Combined With QL1706 (Iparomlimab/Tuvonralimab) Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer.RecruitingNCT07829874Phase 2Report a problem
- Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract CancerRecruitingNCT07704177Phase 2Report a problem
- Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase IINot yet recruitingNCT07686926Phase 2Report a problem
- Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract CancerRecruitingNCT07670273Phase 2Report a problem
- A Study of WGI-0301 Plus Lenvatinib in Patients With Advanced HCCNot yet recruitingNCT07540832Phase 1/2Report a problem
- A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular CarcinomaNot yet recruitingNCT07535840Not applicableReport a problem
- Fostrox Plus Lenvatinib vs Lenvatinib in Advanced Hepatocellular Carcinoma After First-line ImmunotherapyRecruitingNCT07493668Phase 2Report a problem
- TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskRecruitingNCT07487662Phase 2Report a problem
- PULSAR Combined With Fecal Microbiota Transplantation for Advanced Hepatocellular Carcinoma Progressing After First-Line Targeted-ImmunotherapyRecruitingNCT07463248Phase 2Report a problem
- Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCCNot yet recruitingNCT07412054Phase 2Report a problem
- Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney CancerRecruitingNCT07383441Phase 3Report a problem
- MAGNATE-S: Paclitaxel Polymer Micelles Combo in Advanced SarcomaRecruitingNCT07359053Phase 2Report a problem
- Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver CancerNot yet recruitingNCT07282509Phase 1/2Report a problem
- Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 FailureRecruitingNCT07219459Phase 2Report a problem
- Efficacy and Safety of LB1410 Plus Lenvatinib With or Without LB4330 in Advanced Recurrent/Metastatic Cervical CancerNot yet recruitingNCT07177716Phase 2/3Report a problem
- Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract CancerNot yet recruitingNCT07159217Phase 2Report a problem
- Polymeric Micellar Paclitaxel-Based Combination Therapy for Advanced Biliary Tract CancerRecruitingNCT07159204Phase 2Report a problem
- Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell CarcinomaRecruitingNCT07097935Phase 1/2Report a problem
- A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT06986785Phase 2Report a problem
- A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCCNot yet recruitingNCT06984718Phase 2Report a problem
- A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal CancerRecruitingNCT06962787Phase 2Report a problem
- Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)Not yet recruitingNCT06919848Phase 2Report a problem
- Icaritin Soft Capsules+TACE+Immunotherapy+Targeted Therapy Versus TACE+Immunotherapy+Targeted Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT06896396Phase 1/2Report a problem
- A Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursRecruitingNCT06682780Phase 1/2Report a problem
- Gut Microbiota in Liver Cancer (Treated With TKIs In Combination With ICIs)Not yet recruitingNCT06563934Phase 2Report a problem
- Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric CancerNot yet recruitingNCT06499610Phase 4Report a problem
- A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular CarcinomaRecruitingNCT06371157Phase 3Report a problem
- Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular CancerRecruitingNCT06363006Phase 1Report a problem
- Adebrelimab and a TKI in Combination With GEMOX in First-line Treatment of Advanced Biliary Tract Cancers (BTC)RecruitingNCT06320301Phase 2Report a problem
- Efficacy and Safety of Intratumoral Injection of Recombinant Human Adenovirus Type 5 Combined With Tislelizumab and Lenvatinib in the Treatment of Advanced Hepatocellular CarcinomaNot yet recruitingNCT06253598Phase 2Report a problem
- Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High TMEscoreNot yet recruitingNCT06202716Phase 2Report a problem
- The Efficacy and Safety of IBI363 in Solid TumorsRecruitingNCT06081907Phase 1/2Report a problem
- Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular CarcinomaRecruitingNCT06034977Phase 2Report a problem
- Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular CarcinomaNot yet recruitingNCT05903456Phase 2Report a problem
- Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)RecruitingNCT05823987Phase 2Report a problem
- A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05797805Phase 1/2Report a problem
- CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACCRecruitingNCT05774899Phase 1/2Report a problem
- Neoantigen Derived DCs as Cancer TreatmentRecruitingNCT05767684Phase 1Report a problem
- Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study)RecruitingNCT05738616Phase 3Report a problem
- Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05675462Phase 1Report a problem
- Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCCRecruitingNCT05608200Phase 3Report a problem
- Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCCRecruitingNCT05533892Phase 1Report a problem
- the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular CarcinomaRecruitingNCT05408221Phase 2/3Report a problem
- A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)RecruitingNCT05319730Phase 1/2Report a problem
- Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung CancerRecruitingNCT05296603Phase 2Report a problem
- A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard TherapyRecruitingNCT05276310Phase 1Report a problem
- Study of HBV-TCR T Cells (LioCyx-M) as Monotherapy or as Combination With Lenvatinib for HBV-related HCCNot yet recruitingNCT05195294Phase 2Report a problem
- A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular CarcinomaRecruitingNCT05155189Phase 1Report a problem
- Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial CancerRecruitingNCT05112991Phase 2Report a problem
- Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus PemNot yet recruitingNCT05106127Phase 2Report a problem
- Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial CancerNot yet recruitingNCT05077215Phase 3Report a problem
- Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Phase 1/2Report a problem
- GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid TumorsRecruitingNCT04977453Phase 1/2Report a problem
- JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung CancerRecruitingNCT04951947Phase 2Report a problem
- The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined with Lenvatinib in NSCLC.RecruitingNCT04777084Phase 2Report a problem
- A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesRecruitingNCT04300556Phase 1/2Report a problem
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingNCT03486873Phase 3Report a problem
- A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid TumorsCompletedNCT05091346Phase 1/2Results postedReport a problem
- To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid TumorsCompletedNCT05014828Phase 2Results postedReport a problem
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)CompletedNCT05007106Phase 2Results postedReport a problem
- Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)CompletedNCT04740307Phase 2Results postedReport a problem
- Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular CarcinomaCompletedNCT04401800Phase 2Results postedReport a problem
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular CarcinomaActive, not recruitingNCT04194775Phase 3Results postedReport a problem
- Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)CompletedNCT02720068Phase 1Results postedReport a problem
- Safety and Efficacy Study of Lenvatinib Combined With VIC-1911 for the Treatment of Advanced HCCActive, not recruitingNCT06519721Not applicableReport a problem
- Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)Active, not recruitingNCT06462183Phase 1Report a problem
- Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)CompletedNCT06036836Phase 2Report a problem
- Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) MelanomaWithdrawnNCT06030037Phase 2Report a problem
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension StudyActive, not recruitingNCT05899049Phase 3Report a problem
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary CancerActive, not recruitingNCT05775159Phase 2Report a problem
- Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid TumorsStatus unknownNCT05740215Phase 1/2Report a problem
- Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCCTerminatedNCT05718882Not applicableReport a problem
- Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic CancerActive, not recruitingNCT05620134Phase 1/2Report a problem
- IBR900 Cell Injection Combined With Lenvatinib or Bevacizumab in the Treatment of Advanced Primary Liver CancerStatus unknownNCT05411757Early Phase 1Report a problem
- A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)CompletedNCT05342636Phase 1/2Report a problem
- A Phase II Study of AK104 Plus Lenvatinib and TACE in HCCActive, not recruitingNCT05319431Phase 2Report a problem
- Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib for Patients with Advanced Pancreatic CancerCompletedNCT05303090Phase 1Report a problem
- HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular CarcinomaStatus unknownNCT05290220Phase 2Report a problem
- A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)Status unknownNCT05262413Phase 1/2Report a problem
- HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE FailureStatus unknownNCT05135364Phase 2Report a problem
- Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCCStatus unknownNCT05056337Phase 3Report a problem
- KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 AgentTerminatedNCT05001724Phase 2/3Report a problem
- Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)Active, not recruitingNCT04938817Phase 1/2Report a problem
- Study of HX008 in Combination With Bevacizumab or Lenvatinib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)Status unknownNCT04741165Phase 2Report a problem
- A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)Active, not recruitingNCT04736706Phase 3Report a problem
- A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Alone or in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04728321Phase 2Report a problem
- Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)CompletedNCT04700072Phase 1/2Report a problem
- Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)CompletedNCT04626518Phase 1/2Report a problem
- Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)CompletedNCT04626479Phase 1/2Report a problem
- A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)Active, not recruitingNCT04586231Phase 3Report a problem
- The Study of KN046 in Combination With Lenvatinib in Advanced Hepatocellular CarcinomaCompletedNCT04542837Phase 2Report a problem
- Phase III Study of Toripalimab(JS001) Combined With Lenvatinib for Advanced HCCActive, not recruitingNCT04523493Phase 3Report a problem
- A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell CarcinomaActive, not recruitingNCT04522323Phase 1Report a problem
- A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular CarcinomaCompletedNCT04444167Phase 1/2Report a problem
- "Cocktail" Therapy for Hepatitis B Related Hepatocellular CarcinomaStatus unknownNCT04317248Phase 2Report a problem
- Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell CarcinomaTerminatedNCT04203901Phase 2Report a problem
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedNCT04164199Phase 3Report a problem